Stay updated with breaking news from Axillary Hyperhidrosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.
/PRNewswire/ -- The Axillary Hyperhidrosis (AHH): Global Industry Insights, Epidemiology, and Forecast to 2032 report has been added to...
/PRNewswire/ -- The Insight Partners published latest research study on "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
/PRNewswire/ -- The Insight Partners published latest research study on "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment Data presented today in a late-breaking oral presentation at AAD VMX 2021 Management to host an investor call today at 12:00 p.m. EDT BOULDER, Colo., April 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription ...